BEYOND AIR INC XAIR 深 滬
等待開盤 10-06 09:30:00 美东时间
2.43
-0.070
-2.80%
華盛通- 最 高2.53
- 今 開2.53
- 成交量 14.75万股
- 最 低 2.42
- 昨 收 2.50
- 總市值 1269.97万
- 52周最高 13.522
- 市盈率 靜 --
- 換手率 2.82%
- 52周最低 2.02
- 委 比 -92.79%
- 總股本 522.62万
- 歷史最高 328.20
- 量 比 0.85
- 振 幅 4.40%
- 歷史最低 2.42
- 每 手 1
- 風險率 0.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Beyond Air to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
Beyond Air, Inc. announced that its CFO, Douglas Larson, will participate in the ROTH 4th Annual Healthcare Opportunities Conference on October 9, 2025, in New York. The company focuses on harnessing nitric oxide (NO) to treat respiratory illnesses, neurological disorders, and solid tumors. Its FDA-approved LungFit PH system is used for neonates with respiratory failure, while other LungFit systems are under clinical trial for severe lung infecti...
09-22 12:00
Beyond Air Announces New Warrant Agreement
Beyond Air ( ($XAIR) ) has shared an update. On September 8, 2025, Beyond Air a...
09-10 01:57
Beyond Air’s NeuroNOS Gains FDA Orphan Drug Status
The latest announcement is out from Beyond Air ( ($XAIR) ). On September 8, 202...
09-09 05:50
Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds
Beyond Air, Inc. announced the exercise of 1,439,126 existing common stock warrants at a reduced price of $2.21, generating approximately $3.25 million in gross proceeds. The company will issue 719,561 new warrants exercisable at the same price, with immediate exercise and a five-year term. The offering is expected to close on September 9, 2025, with proceeds to fund clinical programs and operating expenses. The new warrants are being offered in ...
09-08 19:55
NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults
NeuroNOS, a subsidiary of Beyond Air, announced that the FDA has granted Orphan Drug Designation to its lead therapy, BA-101, for treating Glioblastoma (GBM), a highly aggressive brain tumor with poor prognosis. Despite current treatments, median survival is less than 12 months, with few advancements in decades. Amir Avniel, NeuroNOS' CEO, highlighted the company's commitment to addressing rare neurological conditions and entering oncology. The d...
09-08 12:00
国产器械首次入围 创新思路不断演进
（来源：中国医药报） 转自：中国医药报 8月13日，被誉为“医药界诺贝尔奖”的Prix Galien USA（以下简称盖伦奖）公布年度“最佳医疗技术”提名名单...
09-04 08:37
Beyond Air Granted Orphan Designation Status For 7-Nitro-1H-indazole For The Treatment Of Malignant Glioma
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1091925
09-03 21:56
Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Beyond Air, Inc. announced that its CEO, Steve Lisi, will participate in the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025, in New York. An on-demand webcast of the Company’s presentation will be available starting September 5, 2025. The Company’s LungFit system, approved for treating neonatal hypoxic respiratory failure, is being advanced for severe lung infections, including COVID-19 and NTM. Beyond Air is als...
09-03 12:00
Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan
Beyond Air公司扩展其LungFit PH全球分销网络，新增日本、韩国等六国，总计覆盖34国，人口27亿。日本由70年经验的AMCO负责。CEO Steve Lisi表示，此举加强了国际市场影响力，正在等待监管审批并提交招标。LungFit PH利用环境空气生成一氧化氮，无需高压气瓶，提升医院效率并减少环境影响，助力 Breath
08-20 12:00
美股大行评级 | 潜在涨幅95.33%！HC Wainwright & Co.上调Insmed目标价至240美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Insmed"买入"评级，目标价从120美元升至240美元；巴克莱：维持Transocean"超配"评级，目标价从3.5美元升至4美元
08-14 09:25
